JP MORGAN/PUT/MODERNA/115/0.1/17.01.25 | Market Closed - Börse Stuttgart 03:51:06 2024-07-12 pm EDT | ||
| 1.45 EUR | +2.11% |
|
| 1 month | +85.90% | ||
| 3 months | -34.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 1.45 | +2.11% |
| 24-07-11 | 1.42 | -11.25% |
| 24-07-10 | 1.6 | -1.84% |
| 24-07-09 | 1.63 | +1.24% |
| 24-07-08 | 1.61 | +8.05% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 03:51 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JL17FF |
| ISIN | DE000JL17FF5 |
| Date issued | 2023-04-21 |
| Strike | 115 $ |
| Maturity | 2025-01-17 (189 Days) |
| Parity | 10 : 1 |
| Emission price | 1.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.06 € |
|---|---|
| Lowest since issue | 0.56 € |
| Spread | 0.08 € |
| Spread % | 5.23% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.5
USD
Average target price
145.9
USD
Spread / Average Target
+20.12%
- Stock Market
- Warrants
- Warrant
